Clinical trial
A Phase IB Multi-Arm Study With Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
NCT02670044 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IB Multi-Arm Study With Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- March 9, 2016
- Completion date
- December 10, 2020
- Enrollment
- 88 (actual)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.